Growth factor receptor transactivation in mediating end organ damage by angiotensin II

Hypertension

Volumn 47, Issue 3, 2006, Pages 339-340

  Suzuki, Hiroyuki ^a   Eguchi, Satoru ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; BCR ABL PROTEIN; CAVEOLIN; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYDROGEN PEROXIDE; IMATINIB; JANUS KINASE 2; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C DELTA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EDITORIAL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERTENSION; LIPID RAFT; MESANGIUM CELL; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSGENIC ANIMAL; VASCULAR SMOOTH MUSCLE; ANIMAL; GENETICS; HUMAN; METABOLISM; NOTE; PATHOPHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; HUMANS; HYPERTENSION; RECEPTORS, GROWTH FACTOR; TRANS-ACTIVATION (GENETICS);

EID: 33644987832     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000202497.83294.50     Document Type: Editorial

References (12)

1. Suzuki H, Motley ED, Frank GD, Utsunimiya H, Eguchi S. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction, and structural requirement. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:305-322.
2. Schellings MWM, Baumann M, van Leeuwen REW, Duisters RFJJ, Janssen SHP, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension. 2006;47:467-474.
3. Saito Y, Berk BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol. 2001;33:3-7.
4. Ohtsu H, Frank GD, Utsunimiya H, Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: Mechanistic insights and its pathophysiology. Antioxid Redox Signal. 2005;7:1315-1326.
5. Mondorf UF, Geiger H, Herrero M, Zeuzem S, Piiper A. Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. FEBS Letters. 2000;472:129-132.
6. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol. 2005;16:363-373.
7. Kim S, Zhan Y, Izumi Y, Yasumoto H, Yano M, Iwao H. In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension. Arterioscler Thromb Vasc Biol. 2000;20:2539-2545.
8. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension. 2004;44:195-202.
9. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem. 2005;280:26592-26599.
10. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 2002;106:909-912.
11. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
12. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005;11:867-874.